Lv2
110 积分 2023-03-26 加入
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
1天前
已完结
Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems
1个月前
已完结
Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems
1个月前
已完结
Abstract CT092: A phase II study of neoadjuvant abemaciclib (LY2835219) in postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (neoMONARCH)
1个月前
已关闭
Targeting CDK4/6 in patients with cancer
1个月前
已完结
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
1个月前
已完结
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
2个月前
已完结
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
2个月前
已完结
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
2个月前
已完结
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
2个月前
已完结
皖公网安备34019202002308
